New clinical focus, Eckert & Ziegler’s Multisource HDR afterloader targets modern brachytherapy

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 7:06 PM ET. Details in the imprint.

With cancer centers under pressure to treat more patients in less time, Eckert & Ziegler’s Multisource high-dose-rate (HDR) afterloader has become one of the company’s key hardware workhorses for modern brachytherapy suites. The system is built around a shielded treatment unit that remotely drives a sealed radioactive source through thin catheters into or near a tumor, allowing high radiation doses in precisely calculated patterns while medical staff remain outside the room.

How the Multisource HDR afterloader supports modern oncology workflows

The Multisource platform is designed as a dedicated HDR brachytherapy afterloader, typically used with iridium-192 or cobalt-60 sources to deliver short, intense treatment sessions for gynecological, prostate, breast and other indications. According to Eckert & Ziegler’s own description, the compact treatment cabinet houses a stepping motor, source storage, drive mechanism and safety interlocks in a single unit that can be installed in shielded rooms with limited space, which is a practical factor for many hospitals upgrading from older equipment. The official product page outlines the system architecture and typical clinical applications.

Clinically, HDR brachytherapy relies on accurate source positioning within flexible applicators or catheters, and the Multisource unit is specified to move the source in small, discrete steps along up to dozens of channels. Multiple dwell positions and dwell times per channel allow treatment planners to shape dose distributions to the target while reducing exposure to surrounding organs. Eckert & Ziegler highlights that the system can be combined with a treatment planning workstation and imaging data so that dose optimization is handled digitally, which helps clinics standardize complex fractionation schedules across patients and indications.

From a safety perspective, HDR afterloaders must prevent unintended source exposure, and the Multisource system includes standard safeguards such as emergency source retraction, door interlocks and continuous position monitoring. The source is stored in a shielded safe inside the unit when not in use; during treatment, cable position sensors track the source path in real time, with automatic retraction if the drive path is interrupted. This kind of remote afterloading design has largely replaced older manual brachytherapy techniques in industrialized markets, where regulators and hospital insurers emphasize occupational exposure limits for staff as well as stringent documentation of each radiation fraction delivered.

In terms of integration, the Multisource platform is aimed at radiation oncology departments that already operate linear accelerators and imaging suites and want to add or renew brachytherapy capacity without rebuilding their entire infrastructure. The afterloader connects via data interfaces to planning systems and hospital information systems, and the manufacturer points to a service offering that covers source replacement, calibration and hardware maintenance on multi-year cycles. This lifecycle support is particularly relevant because HDR sources such as Ir-192 decay with half-lives measured in weeks, requiring regular swaps to maintain prescribed dose rates and predictable treatment times.

Brachytherapy remains a relatively specialized modality compared with external beam radiotherapy, but it is well established in gynecologic and prostate cancer treatment guidelines in Europe and North America. Market analysts tracking the US brachytherapy segment describe a medium-sized but steadily growing market driven by an aging population and refinements in treatment planning and imaging support, even if it remains much smaller than the multi-billion-dollar external beam segment. Recent research on the US brachytherapy market points to continued uptake of HDR systems and associated services through the 2030s.

Within Eckert & Ziegler’s broader portfolio, which spans industrial isotope products and nuclear medicine components, brachytherapy systems like the Multisource HDR afterloader sit in the medical segment that management describes as a strategic growth field alongside radiopharmaceuticals. The company is listed in Germany under ISIN DE0005659700; shares of Eckert & Ziegler closed on Xetra at EUR 15.39 on 06/13/2026, according to recent trading data. The company’s investor relations pages emphasize medical applications as a key pillar of its isotope business.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.